Dianthus Therapeutics, Inc. (DNTH)

Market Cap	608.36M
Revenue (ttm)	2.83M
Net Income (ttm)	-43.56M
Shares Out	29.35M
EPS (ttm)	-8.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,203
Open	21.01
Previous Close	21.32
Day's Range	19.73 - 21.72
52-Week Range	0.57 - 33.77
Beta	n/a
Analysts	Strong Buy
Price Target	41.75 (+101.5%)
Earnings Date	May 7, 2024

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH

Financial Performance

In 2023, DNTH's revenue was $2.83 million, a decrease of -55.96% compared to the previous year's $6.42 million. Losses were -$43.56 million, 53.0% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price forecast is $41.75, which is an increase of 101.50% from the latest price.

Price Target

$41.75

(101.50% upside)

Analyst Consensus: Strong Buy